T1	p 81 136	postmenopausal breast cancer survivors with bone loss :
T2	p 381 425	223 postmenopausal breast cancer survivors .
T3	p 584 645	postmenopausal breast cancer survivors ( BCS ) with bone loss
T4	p 1111 1137	Postmenopausal BCS ( 223 )
T5	i 20 35	weight training
T6	i 227 252	weight training exercises
T7	i 283 304	risedronate , calcium
T8	i 311 320	vitamin D
T9	i 467 475	exercise
T10	i 666 703	risedronate , calcium , and vitamin D
T11	i 896 937	strength/weight training ( ST ) exercises
T12	i 1036 1045	exercised
T13	i 1164 1188	exercise plus medication
T14	i 1192 1207	medication only
T15	i 1263 1270	calcium
T16	i 1285 1294	vitamin D
T17	i 1314 1325	risedronate
T18	i 1343 1351	exercise
T19	i 1375 1387	ST exercises
T20	i 1444 1474	medications without exercising
T21	i 1656 1665	exercised
T22	i 2002 2010	exercise
T23	i 2165 2199	Strength/weight training exercises
T24	o 39 59	bone mineral density
T25	o 64 77	bone turnover
T26	o 349 377	bone mineral density ( BMD )
T27	o 498 501	BMD
T28	o 531 536	BMD .
T29	o 718 746	bone mineral density ( BMD )
T30	o 840 855	bone turnover ;
T31	o 963 966	BMD
T32	o 992 1007	bone turnover ;
T33	o 1097 1102	BMD .
T34	o 1507 1527	BMD at the total hip
T35	o 1544 1549	spine
T36	o 1591 1601	Alkphase B
T37	o 1617 1626	serum NTx
T38	o 1694 1717	BMD at the femoral neck
T39	o 1732 1741	total hip
T40	o 1756 1761	spine
T41	o 1776 1788	total radius
T42	o 1831 1841	Alkphase B
T43	o 1857 1866	Serum NTx
T44	o 1902 1923	BMD and bone turnover
T45	o 2036 2039	BMD
T46	o 2047 2056	total hip
T47	o 2100 2112	femoral neck
T48	o 2220 2223	BMD